Details of Disease

General Information of Disease (ID: DISIXA4Q)

• Disease Name: Neonatal hyperbilirubinemia
• Synonyms: neonatal hyperbilirubinemia; neonatal icterus
• Disease Class: KA87: Neonatal hyperbilirubinaemia
• Definition: OBSOLETE. Jaundice that appears during the neonatal period. In the majority of cases, it appears in the first week of life and is classified as physiologic due to accelerated destruction of erythrocytes and liver immaturity. In a minority of cases it is classified as non-physiologic, appearing in the first twenty four hours after birth, and is associated with underlying diseases including hemolytic disorders, polycythemia, and cephalohematoma.|Reason: is a phenotype and not a disease. Term to consider: neonatal jaundice due to ABO incompatibility
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISIXA4Q: Neonatal hyperbilirubinemia
• ICD Code:
  ICD-11: ICD-11: KA87
  Expand ICD-10: P58,P59,R17
  Expand ICD-9: 773774782.4
• Disease Identifiers:
  MONDO ID: MONDO_0006584
  MESH ID: D051556
  MedGen ID: 208991
  HPO ID: HP:0003265
  SNOMED CT ID: 281610001

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Stannsoporfin	DMEG4TC	Phase 2	Small molecular drug	[1]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] ClinicalTrials.gov (NCT01887327) Study Evaluating the Safety and Efficacy of Two Doses of Stannsoporfin in Combination With Phototherapy in Neonates With Hyperbilirubinemia. U.S. National Institutes of Health.